TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
INO

Inovio Pharmaceuticals Inc

Healthcare · Biotechnology

1.70$ -12.2% vs. previous close Closing price · As of: Nov 3, 2026

Ownership

Ownership Structure

Who owns Inovio Pharmaceuticals Inc (INO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 92.6% of the shares are freely tradable; institutional investors hold 47.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 47.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 92.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 22.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 103Mio.

Largest Shareholders

Institutions

Institutions INO
Name Stake (%) Shares Change (%) Date
FMR Inc 8.18 8,454,797 -9.5 06/30/2026
Jupiter Topco LLC 5.00 5,171,053 +0.0 06/30/2026
Vanguard Capital Management, LLC 3.53 3,650,562 +25.8 06/30/2026
HHG PLC 3.20 3,308,406 +0.0 03/31/2026
Boxer Capital Management, LLC 2.75 2,844,994 +20.0 06/30/2026
ADAR1 Capital Management LLC 2.07 2,143,910 +45.8 06/30/2026
D. E. Shaw & Co LP 1.31 1,351,656 -38.9 06/30/2026

Funds

Funds INO
Name Stake (%) Shares Change (%) Date
Fidelity Small Cap Growth 6.76 6,993,661 +24.2 07/31/2026
Fidelity Small Cap Growth K6 3.42 3,535,483 +25.3 07/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 3.18 3,283,432 +0.0 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?